Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 24 articles:
HTML format
Text format



Single Articles


    January 2017
  1. UEDA Y, Ikegami T, Akamatsu N, Soyama A, et al
    Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2017 Jan 30. doi: 10.1007/s00535-017-1310.
    PubMed     Text format     Abstract available


    December 2016
  2. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    PubMed     Text format     Abstract available


  3. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  4. KUMADA H, Suzuki Y, Karino Y, Chayama K, et al
    The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  5. MORIO K, Imamura M, Kawakami Y, Nakahara T, et al
    ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  6. MORIO R, Imamura M, Kawakami Y, Morio K, et al
    Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  7. CHAYAMA K, Hayes CN
    Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.
    J Gastroenterol. 2016.
    PubMed     Text format    


  8. TOYOTA J, Karino Y, Suzuki F, Ikeda F, et al
    Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  9. IIO E, Shimada N, Abe H, Atsukawa M, et al
    Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  10. TOYODA H, Kumada T, Tada T, Takaguchi K, et al
    Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
    J Gastroenterol. 2016.
    PubMed     Text format    


    February 2016
  11. YOSHIO S, Kanto T
    Host-virus interactions in hepatitis B and hepatitis C infection.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  12. TOYODA H, Kumada T, Tada T, Takaguchi K, et al
    Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  13. SUDA G, Kudo M, Nagasaka A, Furuya K, et al
    Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  14. HIRAMINE S, Sugiyama M, Furusyo N, Uto H, et al
    Erratum to: A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus.
    J Gastroenterol. 2015.
    PubMed     Text format    


    November 2015
  15. KAWAI-KITAHATA F, Asahina Y, Tanaka S, Kakinuma S, et al
    Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  16. HAYASHI N, Nakamuta M, Takehara T, Kumada H, et al
    Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  17. TADA T, Kumada T, Toyoda H, Kiriyama S, et al
    Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  18. UCHIDA Y, Kouyama JI, Naiki K, Sugawara K, et al
    Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  19. TAHATA Y, Hiramatsu N, Oze T, Morishita N, et al
    The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  20. KAI Y, Hikita H, Tatsumi T, Nakabori T, et al
    Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    March 2015
  21. FUJIYOSHI M, Kuno A, Gotoh M, Fukai M, et al
    Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  22. GOTO K, Kato N
    MICA SNPs and the NKG2D system in virus-induced HCC.
    J Gastroenterol. 2015;50:261-72.
    PubMed     Text format     Abstract available


    January 2015
  23. TOSHIMA T, Shirabe K, Ikegami T, Yoshizumi T, et al
    A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis.
    J Gastroenterol. 2015;50:76-84.
    PubMed     Text format     Abstract available


    October 2013
  24. KUDO A , Tanaka S, Ban D, Matsumura S, et al
    Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis.
    J Gastroenterol. 2013.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: